Rallybio founders (L-R): Jeff Fryer, Martin Mackay and Steve Uden

As Sanofi prunes pipeline, ex-Alex­ion crew at Rally­bio picks up ane­mia drug

More than a year af­ter it bought Kymab for $1.5 bil­lion, Sanofi is get­ting rid of a pre­clin­i­cal pro­gram that came with the deal.

Sanofi has out-li­censed its KY1066 an­ti­body to New Haven, CT-based Rally­bio who has re­dubbed it RLYB331. The deal saw Rally­bio make an up­front cash pay­ment of $3 mil­lion to Sanofi in ad­di­tion to promis­ing de­vel­op­ment and com­mer­cial mile­stones and mid to high sin­gle-dig­it roy­al­ties on net sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.